Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

115.75 +19.94 (+20.82%)
Streaming Delayed Price Updated: 1:50 PM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
What's Going On With Novavax Stock?
Novavax, Inc. shares are trading higher Wednesday, and the stock is up by more than 300% over the past month. Here's a look at what's going on. 
Via Benzinga
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in... 
Via Talk Markets
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From Genmab A/S
Via Business Wire
Critical Insights From BioNTech Analyst Ratings: What You Need To Know
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For BioNTech
Via Benzinga
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From BioNTech SE
Via GlobeNewswire
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
Via AB Newswire
Exposures COVID-19
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
From BioNTech SE
Via GlobeNewswire
Jim Cramer: Celestica Makes A 'Comeback,' Sell This Movie Theater Stock,
Jim Cramer called Celestica Inc. "terrific" after the Toronto-based company reported better-than-expected first-quarter financial results. 
Via Benzinga
Moderna Was Among The Best Performing Large-Cap Stocks Last Week (May 20-May 26, 2024): Are They In Your Portfolio?
Top-performing stocks last week were FSLR, MRNA, ELF, NVDA, IP, ADI, FLEX, LOGI, BNTX, and MNDY, boosted by positive news and analyst targets. 
Via Benzinga
Why Vaccine Stocks Rallied This Week
A bird flu outbreak could spur demand for vaccines from these key players, but is it likely? 
Via The Motley Fool
Experts Predict Rise In COVID-19 Cases: Vaccine Stocks Climb
Experts predict a small rise in COVID-19 cases as a newly dominant strain spreads. The new strain, KP.2, represents 28% of Covid infections in the U.S. and experts believe its mutations have made the... 
Via Benzinga
Exposures COVID-19
Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
From BioNTech SE
Via GlobeNewswire
3 Blue-Chip Stocks Set to Triple Soon
Blue-chip stocks are great additions to a portfolio. If you're looking for consistent returns, check out these blue-chip stocks to buy. 
Via InvestorPlace
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Moderna wins a crucial legal battle at the European Patent Office against Pfizer and BioNTech over Covid-19 vaccine patents. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
From BioNTech SE
Via GlobeNewswire
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists. 
Via Benzinga
BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript
BNTX earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q1 2024
BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
What's Going With BioNTech Stock On Monday?
BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by innovative R&D and strong cash reserves. 
Via Benzinga
BioNTech Slides After Reporting Losses As Covid Vaccine Sales Take A Hit
BioNTech missed the Street's sales views and reported wider-than-expected losses. 
Via Investor's Business Daily
Exposures COVID-19
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Wall Street Looks To Extend Rally Amid Caution Over Fed Speeches, More Earnings: Why This Analyst Thinks Bull Market Is Still 'Quite Young'
U.S. stocks are likely to extend their gains as major index futures are modestly higher on Monday. Strong earnings reports continue to support the market, with S&P 500 earnings expected to grow by 5%... 
Via Benzinga
Topics Economy
Exposures Interest Rates
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Specialty Medicines, propelled by strong demand for Arexvy and Shingrix.... 
Via Benzinga
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
What's Going On With Pfizer Stock On Thursday?
GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far. 
Via Benzinga
Topics Stocks
Exposures US Equities
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmaceutical landscape, impacting future innovations and revenue streams. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.